{"filing":{"accession_number":"0001193125-26-267487","cik":"0001641281","ticker":"BOLT","company_name":"Bolt Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"bolt-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/bolt-20260611.htm"},"events":[{"id":5352,"run_id":4689,"accession_number":"0001193125-26-267487","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.","company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6236,"accession_number":"0001193125-26-267487","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:06:25.456627+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6236,"accession_number":"0001193125-26-267487","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:06:25.456627+00:00","company_name":"Bolt Biotherapeutics, Inc.","ticker":"BOLT","filing_date":"2026-06-11"}]}